Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MV-NIS with Cyclophosphamide in Relapsed/Refractory Multiple Myeloma
NCT02192775Phase 2Completed
- Sponsor
- University of Arkansas
- Start
- Mar 2015
- Primary completion
- Aug 2019
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of MV-NIS in multiple myeloma (MM), sponsored by University of Arkansas. Started Mar 2015; status: completed.
02
Drugs
MV-NIS
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02192775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02192775.